Avexitide

Summary

Avexitide (CHEMBL4297949) is a phase-3 clinical-stage protein; indicated across 6 conditions including type 2 diabetes mellitus and hypoglycemia.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 6 conditions
• Clinical trials: 28

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297949
Name	Avexitide
Type	Protein
Max phase	3

Also known as: Avexitida, Avexitide, AVEXITIDE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
type 2 diabetes mellitus	3	MONDO:0005148	MONDO:0005148
hypoglycemia	2	MONDO:0004946	HP:0001943
obesity disorder	2	MONDO:0011122	EFO:0001073
hyperinsulinemic hypoglycemia	2	MONDO:0005803	EFO:0007318
nutritional disorder	1	MONDO:0005137	EFO:0001069

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 28.

Phase distribution

Phase	Trials
Not specified	10
PHASE1	7
PHASE2	6
PHASE4	3
PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01701973	PHASE4	COMPLETED	Effect of DPP4 Inhibition on Growth Hormone Secretion
NCT02844907	PHASE4	TERMINATED	Regulation of Insulin Secretion by the GLP-1 Receptor
NCT03101930	PHASE4	COMPLETED	Cardiovascular Effects of GLP-1 Receptor Activation
NCT06747468	PHASE3	ACTIVE_NOT_RECRUITING	Avexitide for Treatment of Post-Bariatric Hypoglycemia
NCT06967558	PHASE2	RECRUITING	The Role of Islet GLP-1 in the Pathogenesis of Prediabetes
NCT06972407	PHASE2	NOT_YET_RECRUITING	The Effect of rs7903146 Genotype on Islet GLP-1 Production in Humans
NCT00835328	PHASE1/PHASE2	TERMINATED	Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia
NCT02170870	PHASE2	COMPLETED	Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus
NCT02697253	PHASE2	WITHDRAWN	Mechanisms Underlying Predictors of Success From Obesity Surgery
NCT03373435	PHASE2	COMPLETED	Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia
NCT04652479	PHASE2	COMPLETED	Avexitide Safety and Efficacy to Treat Acquired Hyperinsulinemic Hypoglycemia
NCT00468091	PHASE1	COMPLETED	Effects of Exendin(9-39) on Gastroduodenal Motility
NCT00980083	PHASE1	COMPLETED	GLP-1 - Regulatory Mechanism of Postprandial Glycemia
NCT01449019	PHASE1	COMPLETED	The Role of Endogenous Glucagon-like Peptide 1 (GLP-1) in Type 2 Diabetes Mellitus (T2DM)
NCT01795144	PHASE1	COMPLETED	Incretin Regulation of Insulin Secretion in Monogenic Diabetes
NCT01900340	PHASE1	COMPLETED	Intestinal Glucagon-like Peptide-1 (GLP-1) and the Physiological Role in Eating in Humans
NCT02550145	PHASE1	TERMINATED	Role of GLP-1 in Hyperinsulinemic Hypoglycemia Post-bariatric Surgery
NCT02996812	PHASE1	COMPLETED	Evaluation of Single Ascending Doses of Subcutaneous Exendin 9-39 in Patients With Post-Bariatric Hypoglycemia
NCT06498063	Not specified	RECRUITING	The Underlying Mechanisms Regarding the Effect of Glucagon on the Kidneys Will be Investigated in Healthy Males.
NCT07582874	Not specified	AVAILABLE	An Expanded Access Protocol to Provide Avexitide in Patients With Post-Bariatric Hypoglycemia
NCT01281228	Not specified	COMPLETED	The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and Diabetes
NCT01729299	Not specified	UNKNOWN	Ghrelin Effect on Beta Cell Function in Health and Disease
NCT02336659	Not specified	COMPLETED	Influence of Gut Hormones on Food Intake After Roux-en-Y Gastric Bypass Surgery
NCT02746757	Not specified	COMPLETED	Glucagon Like Peptide-1 in Remote Ischemic Conditioning
NCT02971631	Not specified	COMPLETED	Gastrectomy, Eating Behaviour and GLP-1
NCT03241303	Not specified	COMPLETED	Delineation of the Role of Glucagon-like Peptide-1 Signalling in Relation to Increased Carbohydrate Content in the Distal Small Intestines
NCT03246451	Not specified	COMPLETED	The Role of GLP-1 Receptor Signalling in the Glucose-lowering Effect of Metformin in Patients With T2D
NCT07373236	Not specified	COMPLETED	The Effect of Endogenous GLP-1 on Glucagon Secretion in Type 1 Diabetes

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).